Trizivir (AZT/3TC/Abacavir): Research
- The End of the Line for an Induction-Maintenance Approach to HIV Treatment Involving Zidovudine/Lamivudine/Abacavir? (November 14, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
On TheBodyPRO.com
- Zidovudine/Lamivudine/Abacavir May Be Appropriate for Some Treatment-Naive Patients With Low-Baseline Viral Loads (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- HIV JournalView: Induction-Maintenance With Zidovudine/Lamivudine/Abacavir (July/August 2005)
A much-maligned triple-NRTI combo gets a second look as part of a simplification strategy.
In HIV Treatment ALERTS!, from TheBodyPRO.com
- A5095 and the Triple-Nucleoside Saga (January 2005)
A second look at the study that -- at the time -- appeared to doom Trizivir; part of HIV JournalView's Top 10 Research Reports of 2004.
In AIDS Treatment News, from TheBodyPRO.com
- Zidovudine/Lamivudine/Abacavir May Be Effective Alone for Induction Maintenance (July 15, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- Triple-Nucleoside Regimens Versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection (April 29, 2004)
Abstract of results from ACTG 5095, finding Trizivir (AZT/3TC/abacavir) to be far less effective at suppressing viral load than regimens consisting of efavirenz (Sustiva) plus two or three NRTIs.
In New England Journal of Medicine
- Keeping It Real: Don't Believe Everything You Read (October 2003)
Do the recently revealed limitations of Trizivir make it "dangerous"?.
To read PDF, click here.
In HIV Treatment ALERTS!, from The Center for AIDS
- Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- We Want Our Trizivir! (September/October 2003)
IAS 2003 attendees defend the use of Trizivir at the presentation on ACTG 5095.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- AIDS Healthcare Foundation Asks FDA to Withdraw Approval of GSK's Antiretroviral Drug Trizivir (August 20, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- ACTG 5095: Efavirenz-Based Regimens Outperform Triple Nucleoside Combination (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Efavirenz-Based HAART Outperforms a Triple Nucleoside Regimen in Clinical Practice (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Trizivir Often Successful in Treatment-Naive Patients; Resistance Testing Key for Failures (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Another Look at Induction Maintenance Therapy (July 14, 2003)
48-week data on Trizivir and efavirenz in treatment-naive patients.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Is Trizivir Plus Tenofovir Effective in Patients With Possible or Proven Reverse Transcriptase Resistance? (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Trizivir Causes Lowest Triglycerides Rise in Comparison With Combivir + Nelfinavir or d4T (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- The Buzz: Anatomy of a Study -- Trizivir vs. Sustiva (May/June 2003)
A closer look at ACTG 5095, which examined the use of Trizivir and efavirenz in several first-line treatment regimens.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- Abacavir Arm Stopped in Clinical Trial (April 4, 2003)
In AIDS Treatment News, from AIDS Treatment News
On TheBodyPRO.com
|
Advertisement
|
Email
Glossary
